B cells expressing anti-factor VIII alloantibodies

B cells expressing anti-factor VIII alloantibodies are immune cells that produce neutralizing alloantibodies (inhibitors) against factor VIII (FVIII), complicating replacement therapy in hemophilia A patients. These B cells, including memory B cells and plasma cells, develop through antigen presentation in the spleen (e.g., by marginal zone B cells) and are regulated by cytokines like BAFF, which supports their survival, maturation, and maintenance. Elevated BAFF levels correlate with inhibitor presence and predict poor tolerance; targeting BAFF or combining with B cell depletion reduces inhibitors and induces tolerance in models[1][2][3][5].

Other names

anti-FVIII B cellsFVIII-specific B cellsFVIII inhibitor B cellsα-FVIII B cells

BAFF inhibition (prevents survival and maturation of transitional and marginal zone B cells), CD20 depletion (eliminates B cells including plasma cells), High-dose FVIII (inhibits restimulation and differentiation into antibody-secreting plasma cells)